Tenon Medical Inc

Tenon Medical Inc(TNON)股票分析

$1.770

+0.117 (+6.63%)收盘时

Loading chart…
最高
1.800
开盘
1.660
成交量加权均价
1.74
成交量
94.11K
市值
2.31M
最低
1.650
成交额
163.75K
企业价值/息税折旧摊销前利润(TTM)
-0.37

Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant.

AI 分析 of Tenon Medical Inc (TNON)

卖出

Tenon Medical Inc is not a good buy right now due to its extremely low RSI of 13.34, indicating it is oversold, and a staggering year-to-date change of -95.13%. The stock is trading at $1.66, significantly below its 52-week high of $45.50, which reflects a severe decline in value. The company has also reported consistent net losses, with the latest EPS at -12.35, and a forward P/E ratio of 0, suggesting no earnings growth is expected in the near term. The main risk is the negative sentiment surrounding its financing activities, which caused a 4.79% drop in pre-market trading after the announcement of a securities purchase agreement.

估值指标

Tenon Medical Inc(TNON)当前预期市盈率为 0.00,5 年平均预期市盈率为 -3.02。

预期市盈率

合理
5 年均值 P/E
-3.02
当前P/E
0.00
高估
12.73
低估
-18.77

预期 EV/EBITDA

严重低估
5 年均值 EV/EBITDA
-0.05
当前EV/EBITDA
-0.37
高估
0.06
低估
-0.17

预期市销率

合理
5 年均值 P/S
5.63
当前P/S
0.50
高估
36.11
低估
-24.85

Alphio AI 对 TNON 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%TNON

$1.25

情景价格

基

基准

基准 · 50%TNON

$1.02

情景价格

悲

悲观

悲观 · 25%TNON

$0.83

情景价格

事件时间线

2026-10-28 (ET)

09:25:00

Tenon Medical Completes Initial Alpha Cases for Quickstep

2026-10-15 (ET)

09:00:00

Tenon Medical Secures 8 New Patents

2026-10-05 (ET)

06:30:00

Selling Stockholders Plan to Sell 858,269 Shares of Common Stock

2026-09-30 (ET)

09:00:00

Tenon Medical Launches New Titanium 3D-Printed Lateral Screw

2026-09-11 (ET)

11:00:00

Tenon Medical Inc Trading Halted

资讯

TNON 常见问题 —— 由 Alphio AI 解答

Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tenon Medical Inc is not a good buy right now due to its extremely low RSI of 13.34, indicating it is oversold, and a staggering year-to-date change of -95.13%. The stock is trading at $1.66, significantly below its 52-week high of $45.50, which reflects a severe decline in value. The company has also reported consistent net losses, with the latest EPS at -12.35, and a forward P/E ratio of 0, suggesting no earnings growth is expected in the near term. The main risk is the negative sentiment surrounding its financing activities, which caused a 4.79% drop in pre-market trading after the announcement of a securities purchase agreement.

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易